Biotechnology company Moderna has partnered with OpenAI to incorporate advanced AI into their operations for the enhancement of mRNA medicine.
The collaboration involves utilizing OpenAI's GenAI tools across Moderna's organization. Early success was seen in the adaptation of a ChatGPT platform named "mChat." This technological incorporation helps the latter's various business functions, such as legal, research, and manufacturing.
The objective is to deploy AI to address complicated problems and facilitate the development of new-generation medicines. This approach has already resulted in the launch of over 750 GPTs within Moderna, significantly improving the process of automation and productivity.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.